BL&H acquires Trisenox licence for South Korea
This article was originally published in Scrip
Executive Summary
Nippon Shinyaku has sublicensed Cephalon's arsenic trioxide product Trisenox to BL&H for development and marketing in South Korea. The therapy, to which the Japanese firm acquired exclusive marketing rights in Japan, South Korea and Taiwan in late 2002, will be developed by BL&H for relapsed or refractory acute promyelocytic leukaemia (APL), its main indication. The disease affects around 250 people a year in South Korea, noted Nippon Shinyaku, which will receive undisclosed development milestones as part of the deal. Trisenox was launched for APL in Japan around four years ago.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.